Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk
Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
Omada Health (NASDAQ:OMDA) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Omada Health (NASDAQ:OMDA) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
2026: When Women's Sport Becomes Healthcare's Most Powerful Platform [Forbes]